Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04383067
Other study ID # SHEBA-19-6407-RS-TIL TCC
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 12, 2020
Est. completion date June 1, 2023

Study information

Verified date May 2020
Source Sheba Medical Center
Contact Ronnie Shapira, MD.
Phone +972-3-5308414
Email Ronnie.Shapira@sheba.health.gov.il
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients.


Description:

This is a phase II single-center study of Tumor Infiltrating Lymphocytes (TIL) in urothelial carcinoma patients who failed at least one line of platinum based chemotherapy and one line of immunotherapy of targeted therapy. Patients will undergo a baseline evaluation including imaging, blood and urine samples, EVG and physical examination to confirm suitability for the study. Eligible patients will undergo surgery to collect a tumor sample for TIL culturing. Patients will receive an autologus TIL infusion once the cells have been properly cultured. Following the infusion, patients will receive a high dose of IL-2. Following the intervention, patients will be monitored to evaluate study endpoints.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date June 1, 2023
Est. primary completion date June 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Histologically confirmed Urothelial Carcinoma 2. Progressed on first line platinum-based chemotherapy and on second line immunotherapy or targeted therapy (FGFR inhibitor) 3. Measurable metastatic Urothelial Carcinoma with at least one lesion that is resectable for TIL generation. 4. Patients with one or more brain metastases less than 1 cm each, and any patients with 1 or 2 brain metastases greater than 1 cm must have been treated and stable for 4 weeks. 5. Greater than or equal to 18 years of age. 6. Willing to practice birth control from the start of chemotherapy until 120 days after release from the hospital. 7. Life expectancy of greater than three months 8. Willing to sign a durable power of attorney 9. Able to understand and sign the Informed Consent Document 10. Clinical performance status of ECOG 0 or 1 11. Hematology: - Absolute neutrophil count greater than 1000/mm3 without support of filgrastim - Normal WBC ( > 3000/mm3). - Hemoglobin greater than 8.0 g/dL - Platelet count greater than 100,000/mm3 12. Serology: - Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune competence and thus can be less responsive to the experimental treatment and more susceptible to its toxicities.) - Seronegative for Hepatitis B or Hepatitis C. (patients who recovered from previous infection and have no detected HBSAg or HCV RNA are allowed). 13. Chemistry: - Serum ALT/AST less than three times the upper limit of normal (ULN). - Serum creatinine less than or equal to 1.6 mg/dL - Total bilirubin no more than x1.5 times the ULN, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3 mg/dL. 14. Negative pregnancy test in women of child bearing potential because of the potentially dangerous effects of the preparative chemotherapy on the fetus. 15. More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo). Patients may have undergone minor surgical procedures with the past 3 weeks, as long as all toxicities have recovered to grade 1 or less. Exclusion Criteria: 1. Upper tract Urothelial Carcinoma 2. History of nephrectomy 3. Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the non-myeloablative, lymphodepleting induction regimen on the fetus or infant. 4. Systemic steroid therapy required (patients that require replacement therapy for adrenal insufficiency may be enrolled if steroid treatment dose do not exceed 10 mg of prednisone or equivalent). 5. Active systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease. 6. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease and AIDS). 7. Opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities.) 8. History of severe immediate hypersensitivity reaction to any of the agents used in this study, including history of an anaphylactic reaction to penicillin or gentamicin 9. History of coronary revascularization or ischemic heart disease. 10. Any patient known to have an LVEF less than or equal to 50%. 11. Documented LVEF of less than or equal to 50% tested in patients with clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second- or third-degree heart block 12. Documented FEV1 and DLCO (relative to predicted) less than or equal to 60%

Study Design


Intervention

Procedure:
Tumor Infiltrating Lymphocytes (TIL)
Patient with metastatic urothelial carcinoma will undergo a autologous lymphocyte transplantation. Patient will undergo surgery to remove either the primary tumor or a tumor metastasis. The cells collected in this surgey will be cultured and reintroduced to the patient. Following the cell infusion, patient will receive a high-dose bolus of IL-2.
Drug:
Proleukin
high-dose (720,000 IU/kg) IL-2 will be administered every 8 hours, to tolerance. A maximum of 10 doses will be administered

Locations

Country Name City State
Israel Sheba Medical Center Ramat Gan

Sponsors (1)

Lead Sponsor Collaborator
Sheba Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Other Tissue markers assessment Tissue markers such as protein expression 3 Years
Other Blood Bio-markers assessment Blood Bio-markers, including Circulating factors and peripheral blood mononuclear cell phenotype and function 3 Years
Primary Efficacy endpoint Objective Tumor response according to RECICT 1.1 The primary efficacy endpoint is defined as at least a 20% clinical benefit expressed as the sum of CR+PR+SD (each of these parameters defined as persisting for at least for 12 weeks). 3 Years
Primary Safety endpoint Assess Adverse Events using CTCAE V4.03 during treatment and FU The primary safety endpoint of the study is to evaluate the overall toxicity profile of the ACT procedure, with an emphasis on the side effects of the reduced intensity, non-myeloablative, lymphodepleting induction regimen. 3 Years
Secondary Overall Survival Overall Survival (OS) according to RECICT 1.1 3 Years
Secondary Progression-Free Survival Progression-Free Survival (PFS) according to RECICT 1.1 3 Years
Secondary Quality of Life (QoL) Assessment Assessment of QoL using disease specific modules of the EORTC QLQ-C30 (version 3.0) 3 Years
See also
  Status Clinical Trial Phase
Completed NCT05700344 - SOGUG-AVELUMAB_RWD
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Recruiting NCT04953104 - Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression Phase 2
Withdrawn NCT06050954 - A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA) Phase 2
Active, not recruiting NCT03534804 - Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma Phase 2
Active, not recruiting NCT00365157 - Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Phase 1/Phase 2
Withdrawn NCT06018116 - A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer. Phase 2
Recruiting NCT05544552 - Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations Phase 1/Phase 2
Recruiting NCT04936230 - Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer Phase 2
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Terminated NCT05052372 - Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Terminated NCT03115801 - A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers Phase 2
Active, not recruiting NCT03854474 - Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma Phase 1/Phase 2
Terminated NCT02693717 - Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer Phase 2
Recruiting NCT04848519 - Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma Phase 2
Active, not recruiting NCT04724018 - Sacituzumab Govitecan Plus EV in Metastatic UC Phase 1
Terminated NCT04003610 - Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) Phase 2
Not yet recruiting NCT03108261 - Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations Phase 2
Recruiting NCT05733000 - CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Phase 2